Commerce Dashboard

Go Back

Dr Reddy's launches generic product in US to treat gastroesophageal reflux disease

IBEF:  October 21, 2020

On Tuesday, Dr. Reddy's Laboratories said it had launched the over-the-counter (OTC) medication Famotidine tablets on the American market, used to treat gastroesophageal reflux disease.

"After receiving approval from the US Food and Drug Administration (USFDA), the company has launched the medication, which is like Johnson & Johnson's Pepcid AC, in the US," Dr. Reddy's Laboratories said in a statement.

Famotidine tablets are used to avoid and alleviate acid indigestion and sour stomach-related heartburn caused by consuming or drinking certain foods and drinks.

Dr. Reddy’s Laboratories North America Generics CEO Mr. Marc Kikuchi said, "This launch will help us fulfil an important therapy gap created in antacids market due to Ranitidine withdrawal”.

For the 12 months ending in August 2020, the Pepcid AC brand and generic variants had US sales of about $211 million.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.